The clinical impact of methotrexate dose reduction at combination therapy with adalimumab plus methotrexate in rheumatoid arthritis; ALIBABA study
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-UMIN000024025
- Lead Sponsor
- Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Not provided
1. An autoimmune disease patient except RA which can affect the inflammatory views 2. The patient receiving the following treatments within four weeks before baseline The increase of glucocorticoid (GC) dosage or newly administration of GC 3. Plasma pheresis 4. The surgical management that it is thought to affect the efficacy evaluation 5. The patient who uses GC more than 5 mg a day 6. A patient with a history of administration of ADA 7. A patient (less than two weeks before therapeutic drug dosage start) less than number of the lymphocytes 1,000 per micro litter 8. The patient with severe infectious diseases 9. A pregnant or nursing woman, the woman who may be pregnant, the woman in hope of the pregnancy and the partner 10. The patient who participates in the clinical trials such as similar effect therapeutic drugs now
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method